Roivant Sciences (ROIV) Receives a Buy from TD Cowen
In a report released today, Yaron Werber from TD Cowen maintained a Buy rating on Roivant Sciences (ROIV – Research Report). The company’s ...
Investor's Business Daily on MSN2d
Roivant And Immunovant Won't Seek Approval Despite Phase 3 Win. Why Shares Rose.
Immunovant and Roivant Sciences said Wednesday their rare disease drug succeeded in a final-phase study, but the duo won't seek approval.
The Pharma Letter2d
Positive batoclimab data from Immunovant, but doubts raised on further development
Immunovant (Nasdaq: IMVT), a Roivant Sciences company, today reported top-line results from its Phase III study of batoclimab ...
STAT2d
Cargo Therapeutics ends development efforts
Cargo was founded by two highly acclaimed cell-therapy researchers. The company raised over $500 million to develop ...
Roivant Announces Positive Results for Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Studies
Pivotal study in MG met primary endpoint of change from baseline in MG-ADL in AChR+ population at 12 weeks, with a 5.6 point improvement in the ...
Immunovant, Roivant slip after trial data for autoimmune disorder therapy
Immunovant's (NASDAQ:IMVT) stock and Roivant Sciences (ROIV) stock fall after trial data for the former's autoimmune disease ...
STAT2d
Immunovant and Roivant report success in autoimmune drug’s Phase 3 trial
The companies reported Wednesday that batoclimab showed improvements in myasthenia gravis patients in a Phase 3 trial.
BioWorld2d
En garde, Vyvgart: Immunovant rolls out MG data
Roivant Sciences Ltd. CEO Matt Cline said the firm’s unit Immunovant Inc. with FcRn blocker batoclimab has established “frankly a new bar” in myasthenia gravis (MG) as the New York-based firm reported ...
The Manila Times3d
J'JO's findings shed light on need and value for more crypto index investing
J'JO doesn't handle users' funds: Users aren't required to transfer their funds to J'JO as all investments and assets remain ...